gemcitabine + cisplatin + durvalumab + spatially fractionated radiotherapy + deep hyperthermia

This experimental therapeutic regimen, being evaluated by the University of Maryland, Baltimore, combines a standard-of-care chemoimmunotherapy backbone with localized physical interventions for the treatment of advanced, unresectable biliary tract cancer and cholangiocarcinoma. The systemic component consists of gemcitabine (a nucleoside metabolic inhibitor), cisplatin (a platinum-based antineoplastic), and durvalumab (a PD-L1 blocking monoclonal antibody). Gemcitabine and cisplatin work synergistically to inhibit DNA synthesis and induce cytotoxic damage, while durvalumab restores anti-tumor immune responses by preventing PD-L1 from binding to PD-1 and B7.1. This systemic therapy is augmented with spatially fractionated radiotherapy (SFRT), which delivers high-dose radiation to specific tumor volumes, and deep hyperthermia (HT), which uses heat to increase tumor blood flow and oxygenation. The combination is hypothesized to enhance local tumor control and improve systemic efficacy in patients with large or unresectable lesions.

Brand names

GemzarPlatinolImfinzi

Other names

GemCisDur + SFRT + HTChemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy